Seres Therapeutics, Inc. (NASDAQ:MCRB) Given Average Recommendation of “Moderate Buy” by Brokerages
Seres Therapeutics, Inc. (NASDAQ:MCRB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the five analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among analysts […]
More Stories
Bridgerton Season 5: Release Date, Cast, Teaser, and Recent Updates
Fans’ favourite series, Bridgerton season 5, is coming back soon. The series’ official network, Netflix, has officially announced the renewal....
CBP to Begin First Phase of Tariff Refunds Following Supreme Court Ruling
By Aldgra Fredly U.S. Customs and Border Protection (CBP) is set to begin the first phase of its refund process...
2 US Embassy Employees, 2 Mexican Officials Killed in Car Crash
By Aldgra Fredly Two instructor officers from the U.S. Embassy in Mexico and two Mexican officials died in a car...
Beyond Hormuz: The US–Indonesia Defense Pact and What It Means for China
By Antonio Graceffo The U.S.–Indonesia defense pact strengthens American strategic control over key maritime chokepoints, enhancing its ability to pressure...
Iran Signals It May Skip Next US-Led Peace Talks as Israel Warns of Renewed Fighting
By Tom Ozimek Iran signaled fresh uncertainty around U.S.-backed peace efforts on April 20, saying it has yet to decide...
Is Love Story Season 2 Renewed? Release Date, Cast, and Spoiler
Ryan Murphy’s latest series, Love Story Season 1, has raised the bar with the 90’s romance featuring Sarah Pidgeon and...